Sage Capital Advisors llc Purchases 157 Shares of Quest Diagnostics Inc (NYSE:DGX)

Share on StockTwits

Sage Capital Advisors llc boosted its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,843 shares of the medical research company’s stock after acquiring an additional 157 shares during the quarter. Sage Capital Advisors llc’s holdings in Quest Diagnostics were worth $1,692,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Quest Diagnostics by 0.6% in the second quarter. Vanguard Group Inc. now owns 14,963,272 shares of the medical research company’s stock worth $1,523,411,000 after buying an additional 89,648 shares during the last quarter. State Street Corp boosted its stake in shares of Quest Diagnostics by 0.8% during the 3rd quarter. State Street Corp now owns 6,342,331 shares of the medical research company’s stock worth $678,820,000 after acquiring an additional 48,167 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Quest Diagnostics by 12.1% during the 2nd quarter. Victory Capital Management Inc. now owns 3,188,068 shares of the medical research company’s stock worth $324,577,000 after acquiring an additional 344,767 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Quest Diagnostics by 11.6% during the 2nd quarter. Bank of America Corp DE now owns 2,214,964 shares of the medical research company’s stock worth $225,505,000 after acquiring an additional 230,620 shares in the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in shares of Quest Diagnostics by 33.7% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,780,582 shares of the medical research company’s stock worth $181,281,000 after acquiring an additional 448,332 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 target price on the stock in a research note on Monday, September 30th. ValuEngine cut shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, November 29th. Barclays cut shares of Quest Diagnostics from an “overweight” rating to an “equal weight” rating and set a $106.00 target price on the stock. in a research note on Tuesday, January 7th. Bank of America cut shares of Quest Diagnostics from a “neutral” rating to an “underperform” rating in a research note on Friday, January 3rd. Finally, UBS Group lowered their target price on shares of Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating on the stock in a research note on Monday, October 21st. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. Quest Diagnostics has a consensus rating of “Hold” and a consensus price target of $106.07.

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 44,556 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $107.43, for a total value of $4,786,651.08. Following the transaction, the senior vice president now owns 51,321 shares of the company’s stock, valued at $5,513,415.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gail R. Wilensky sold 8,000 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $107.17, for a total transaction of $857,360.00. Following the completion of the transaction, the director now directly owns 22,951 shares in the company, valued at approximately $2,459,658.67. The disclosure for this sale can be found here. Corporate insiders own 1.86% of the company’s stock.

Shares of DGX stock traded up $0.44 on Thursday, hitting $107.17. 115,195 shares of the stock traded hands, compared to its average volume of 612,105. The firm’s 50-day moving average price is $106.33 and its two-hundred day moving average price is $103.69. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.83 and a current ratio of 0.88. The stock has a market capitalization of $14.38 billion, a PE ratio of 16.98, a PEG ratio of 2.09 and a beta of 0.85. Quest Diagnostics Inc has a twelve month low of $82.59 and a twelve month high of $108.95.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.71 by $0.05. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. The firm had revenue of $1.96 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the company posted $1.68 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts anticipate that Quest Diagnostics Inc will post 6.49 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be given a $0.53 dividend. The ex-dividend date is Monday, January 13th. This represents a $2.12 dividend on an annualized basis and a yield of 1.98%. Quest Diagnostics’s payout ratio is currently 33.60%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More: How to build a Fibonacci channel

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.